Study on an Optimal Antiviral Treatment in HBeAg Positive Chronic Hepatitis B Patients
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The current study is a prospective, randomized, open, multi-center investigation. The aim of
the study is to investigate whether the HBeAg seroconversion rate can be improved if applying
combination therapy in HBeAg positive CHB patients who has achieved
HBVDNA<105copies/ml，HBsAg≤5000IU/ml, ALT≥ 2ULN or Liver histology G2S2.